Abstract: One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.
Abstract: The inventive subject matter relates to a construct comprising antigens derived from multiple enterobacteria including Campylobacter jejuni capsule polysaccharide polymer, enterotoxigenic Escherichia coli recombinant polypeptide construct and lipopolysaccharide from Shigella spp. The subject invention also relates to a method of inducing an immune response utilizing the inventive composition.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
October 23, 2018
Assignee:
The United States of America as represented by the Secretary of the Navy
Inventors:
Patricia Guerry, Mario Artur Monteiro, Stephen Savarino
Abstract: The present invention is directed to the cells, compositions and methods for the production of recombinant protein. In particular, the invention is directed to a production process for obtaining high levels of soluble recombinant CRM197 protein from E. coli. Cells preferably contain one or more mutations of disulfide reductase genes, so that disulfide reductase activity is reduced. The invention also relates to purification method for CRM197 as well as characterization of properly folded CRM197 protein.
Abstract: The present disclosure provides for methods of diagnosing and treating bacterial infections. Human Intelectin 1 (hIntL-1) has been shown to bind selectively to glycan components on bacteria including Streptococcus pneumonia, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumonia and Yersinia pestis. This interaction can be targeted to identify, purify and therapeutically target such organisms.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
September 25, 2018
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Laura L. Kiessling, Darryl A. Wesener, Kittikhun Wangkanont
Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
Type:
Grant
Filed:
December 13, 2016
Date of Patent:
August 14, 2018
Assignee:
The University of Chicago
Inventors:
Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carla Emolo, Andrea DeDent
Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.
Type:
Grant
Filed:
September 7, 2016
Date of Patent:
July 24, 2018
Assignee:
INTREXON ACTOBIOTICS NV
Inventors:
Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
Abstract: A method for separating a biological conjugate from an aggregate. The molecular weight of the biological conjugate ranges from about 10 kDa to about 1000 kDa. In one embodiment, the method comprises the steps of: (e) providing a mixture comprising the biological conjugate and the aggregate, wherein the biological conjugate has a molecular weight of from about 10 kDa to about 1000 kDa; (f) providing a chromatography column containing a gel, wherein the gel comprises at least one polysaccharide; (g) introducing the mixture of step (a) into the chromatography column; (h) recovering the biological conjugate from the column.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
July 17, 2018
Assignee:
Abbott Laboratories
Inventors:
Marcela De Leon Gatti, Yingqing Huang, David K. Schisla, Lou-Hwa J. Sheu, Christopher A. Tomas
Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
Type:
Grant
Filed:
February 18, 2016
Date of Patent:
July 17, 2018
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Normand Blais, Steve Labbe, Jan Poolman
Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.
Type:
Grant
Filed:
November 30, 2012
Date of Patent:
July 17, 2018
Assignee:
INTEGRATED BIOTHERAPEUTICS, INC
Inventors:
Mohammad Javad Aman, Rajan Prasad Adhikari, Hatice Karauzum, Jawad Sarwar, Sergey Shulenin, Sathya Venkataramani, Kelly Lyn Warfield, Tam Luong Nguyen
Abstract: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli, including enterotoxigenic Escherichia coli, to human cells.
Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
June 5, 2018
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Renata Maria Grifantini, Oretta Finco, Erika Bartolini, Guido Grandi
Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.
Type:
Grant
Filed:
December 28, 2009
Date of Patent:
May 1, 2018
Assignee:
REVANCE THERAPEUTICS, INC.
Inventors:
Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
Abstract: Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
May 1, 2018
Assignee:
GRIFOLS, S.A.
Inventors:
David Ownby, Thomas P. Zimmerman, Jennifer A. Hunt, Charles Miller, Senthil Ranganathan, Tonny Dessources